GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (STU:EZ1) » Definitions » EV-to-FCF

Enzon Pharmaceuticals (STU:EZ1) EV-to-FCF : -26.19 (As of Jun. 03, 2024)


View and export this data going back to . Start your Free Trial

What is Enzon Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Enzon Pharmaceuticals's Enterprise Value is €-33.55 Mil. Enzon Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €1.28 Mil. Therefore, Enzon Pharmaceuticals's EV-to-FCF for today is -26.19.

The historical rank and industry rank for Enzon Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:EZ1' s EV-to-FCF Range Over the Past 10 Years
Min: -347.94   Med: 1.37   Max: 268.5
Current: -26.22

During the past 13 years, the highest EV-to-FCF of Enzon Pharmaceuticals was 268.50. The lowest was -347.94. And the median was 1.37.

STU:EZ1's EV-to-FCF is ranked better than
99.74% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs STU:EZ1: -26.22

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Enzon Pharmaceuticals's stock price is €0.105. Enzon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.000. Therefore, Enzon Pharmaceuticals's PE Ratio for today is N/A.


Enzon Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Enzon Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals EV-to-FCF Chart

Enzon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 -28.30 44.36 43.52 -30.70

Enzon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.96 -51.12 -36.40 -30.70 -28.12

Competitive Comparison of Enzon Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Enzon Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's EV-to-FCF falls into.



Enzon Pharmaceuticals EV-to-FCF Calculation

Enzon Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-33.551/1.281
=-26.19

Enzon Pharmaceuticals's current Enterprise Value is €-33.55 Mil.
Enzon Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzon Pharmaceuticals  (STU:EZ1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Enzon Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.105/0.000
=N/A

Enzon Pharmaceuticals's share price for today is €0.105.
Enzon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Enzon Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals (STU:EZ1) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.

Enzon Pharmaceuticals (STU:EZ1) Headlines

No Headlines